Familial defective apolipoprotein B-100: A study of patients from lipid clinics in Scotland and Wales

Annals of Clinical Biochemistry

Volumn 33, Issue 5, 1996, Pages 443-450

  Wenham, Philip R ^c   Bloomfield, Peter ^a   Blundell, Gillian ^c   Penney, Michael D ^b   Rae, Peter W H ^a   Walker, Simon W ^a  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^b ROYAL GWENT HOSPITAL   (United Kingdom)

^c WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Familial defective apolipoprotein B 100; Hypercholesterolaemia

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN B100; ARGININE; BEZAFIBRATE; CHOLESTEROL; COLESTYRAMINE; GLUTAMINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SIMVASTATIN;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; AUTOSOMAL DOMINANT DISORDER; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA DETERMINATION; FAMILIAL DEFECTIVE APOLIPOPROTEIN B100; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILY HISTORY; FEMALE; GENE MUTATION; HAPLOTYPE; HETEROZYGOTE; HUMAN; ISCHEMIC HEART DISEASE; LIPID ANALYSIS; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PEDIGREE ANALYSIS; POINT MUTATION; PRIORITY JOURNAL;

EID: 0029836579     PISSN: 00045632     EISSN: None     Source Type: Journal    
DOI: 10.1177/000456329603300508     Document Type: Article

References (30)

1. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986; 232: 34-47
2. Innerarity TL, Mahley RW, Weisgraber KH, Bersot TP, Krauss RM, Vega GL, et al. Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolaemia. J Lipid Res 1990; 31: 1337-49
3. Tybjærg-Hansen A, Humphries SE. Familial defective apolipoprotein B-100: a single mutation that causes hypercholesterolaemia and premature coronary artery disease. Atherosclerosis 1992; 96: 91-107
4. Myant NB. Familial defective apolipoprotein B-100: a review, including some comparisons with familial hypercholesterolaemia. Atherosclerosis 1993; 104: 1-18
5. Soria LF, Ludwig EH, Clark HRG, Vega GL, Grundy SM, McCarthy BJ. Association between a specific apolipoprotein B mutation and familial defective apolipoprotein B-100. Proc Natl Acad Sci USA 1989; 86: 587-91
6. Innerarity TL, Weisgraber KH, Arnold KS, Mahley RW, Krauss RM, Vega GL, et al. Familial defective apolipoprotein B-100: low density lipoprotein with abnormal receptor binding. Proc Natl Acad Sci USA 1987; 84: 6919-23
7. Weisgraber KH, Innerarity TL, Newhouse YM, Young SG, Arnold KS, Krauss RM, et al. Familial defective apolipoprotein B-100: enhanced binding of monoclonal antibody MB47 to abnormal low density lipoproteins. Proc Natl Acad Sci USA 1988; 85: 9758-62
8. Tybjærg-Hansen A, Gallagher J, Vincent J, Houlston R, Talmud P, Dunning AM, et al. Familial defective apolipoprotein B-100: detection in the United Kingdom and Scandinavia, and clinical characteristics of ten cases. Atherosclerosis 1990; 80: 235-42
9. Schuster H, Rauh G, Kormann B, Hepp T, Humphries S, Keller C, et al. Familial defective apolipoprotein B-100. Comparison with familial hypercholesterolaemia in 18 cases detected in Munich. Arteriosclerosis 1990; 10: 577-81
10. Myant NB, Gallagher JJ, Knight BL, McCarthy SN, Frostegård J, Nilsson A, et al. Clinical signs of familial hypercholesterolaemia in patients with familial defective apolipoprotein B-100 and normal low density lipoprotein function. Arterioscler Thromb 1991; 11: 691-703
11. 100: clinical characteristics of 54 cases. Atherosclerosis 1992; 92: 233-41
12. Scientific Steering Committee on behalf of the Simon Broome Register Group. Risk of fatal coronary heart disease in familial hypercholesterolaemia. BMJ 1991; 303: 893-6
13. Friedewald WT, Levy RI, Frederickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502
14. Miller SA, Dykes DD, Polesky HF. A simple salting-out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215
15. Motti C, Funke H, Rust S, Dergunov A, Assman G. Using mutagenic polymerase chain reaction primers to detect carriers of familial defective apolipoprotein B-100. Clin Chem 1991; 37: 1762-6
16. Priestley L, Knott T, Wallis S, Powell L, Pease R, Simon A, et al. RFLP for the human apolipoprotein B gene: i, Bam HI; ii, Eco RI; iii, Eco RV; iv, Msp I; v, Xba I. Nucleic Acids Res 1985; 13: 6789-93
17. Huang L-S, de Graff J, Breslow JL. Apo B gene Msp I RFLP in exon 26 changes amino acid 3611 from Arg to Gln. J Lipid Res 1988; 29: 63-7
18. Shoulders CC, Myant N, Sidoli A, Rodriguez JC, Cortese C, Baralle FE, et al. Molecular cloning of human apolipoprotein B cDNA: evidence for more than one gene per haploid genome. Atherosclerosis 1985; 58: 277-89
19. Leitersdorf E, Chakravarti A, Hobbs HH. Polymorphic DNA haplotypes at the LDL receptor locus. Am J Hum Genet 1989; 44: 409-21
20. Jensen LG, Jensen HK, Kjeldsen M, Gerdes LU, Hansen PS, Færgeman O, et al. A new highly informative Sma I polymorphism in intron 7 of the low density lipoprotein receptor (LDLR) gene. Clin Genet 1994; 45: 52-3
21. Leitersdorf E, Hobbs HH. Human LDL receptor gene: Hinc II polymorphism detected by gene amplification. Nucleic Acids Res 1988; 16: 7215
22. Bersot TP, Russell SJ, Thatcher SR, Pomernacki NK, Mahley RW, Weisgraber KH, et al. A unique haplotype of the apolipoprotein B-100 allele associated with familial defective apolipoprotein B-100 discovered during a study of the prevalence of the disorder. J Lipid Res 1993; 34: 1149-54
23. Hansen PS, Nørgaard-Petersen B, Meinertz H, Jensen HK, Hansen ABB, Klausen IC, et al. Incidence of the apolipoprotein B-3500 mutation in Denmark. Clin Chim Acta 1994; 230: 101-4
24. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986; 232: 34-7
25. Friedl W, Ludwig EH, Balestra ME, Arnold KS, Paulweber B, Sandofer F. Apolipoprotein B gene mutations in Austrian subjects with heart disease and their kindred. Atherosclerosis 1991; 11: 371-8.
26. Loux N, Saint-Jore B, Collod G, Benlian P, Canbou JP, Denat M, et al. Identification of the haplotype associated with the APOB-3500 mutation in a French hypercholesterolaemic subject: further support for a unique European ancestral mutation. Hum Mutat 1993; 2: 145-7
27. Corsini A, Mazzotti M, Fumugalli R, Catapano AL, Romano L, Romano C. Poor response to simvastatin in familial defective apolipoprotein B-100. Lancet 1991; 337: 305
28. Maher VMG, Gallagher JJ, Thompson GR, Myant NB. Response to cholesterol-lowering drugs in familial defective apolipoprotein B-100. Atherosclerosis 1991; 91: 73-6
29. Illingworth DR, Vaker F, Mahley RW, Weisgraber KH. Hypocholesterolaemic effects of lovastatin in familial defective apolipoprotein B-100. Lancet 1992; 339: 598-600
30. Schmidt EB, Illingworth DR, Bacon S, Mahley RW, Weisgraher KH. Hypocholesterolaemic effects of cholestyramine and colestipol in patients with familial defective apolipoprolein B-100. Atherosclerosis 1993; 98: 213-7